<DOC>
	<DOCNO>NCT01050699</DOCNO>
	<brief_summary>The central purpose proposal study short-term effect sedation sympatholysis , use α2 adrenergic agent Dexmedetomidine , sleep inflammation critically ill patient Acute Lung Injury Acute Respiratory Disorder Syndrome ( ALI/ARDS ) . An additional objective determine effect Dexmedetomidine sedation in-vitro production sleep-modulating inflammatory cytokine peripheral blood mononuclear cell critically ill patient ALI/ARDS .</brief_summary>
	<brief_title>Sleep Intervention During Acute Lung Injury</brief_title>
	<detailed_description>Critically ill patient acute lung injury acute respiratory distress syndrome ( ALI/ARDS ) receive mechanical ventilation suffer severe sleep disruption despite continuous sedative infusion . Sleep disruption , turn , may activate sympathetic nervous system cause elevation circulate inflammatory cytokine , , turn , may play causative role delirium post-traumatic stress disorder consolidation unpleasant memory awakening sleep . Currently , little understanding inter-relationship critical illness , sleep , neuropsychological well-being , due lack intervention-based trial improve sleep critical illness . The central purpose proposal study short-term effect sedation sympatholysis ( central α2 adrenergic agent ) sleep inflammation critically ill patient ALI/ARDS . Sedation sympatholysis achieve novel sleep-promoting agent central α2 adrenergic property . This FDA approve novel sedative agent , dexmedetomidine , show decrease delirium ( independent predictor mortality ) decrease duration mechanical ventilation ICU stay critically ill patient receive mechanical ventilation ( Riker et al , JAMA 2009 ; 301:542-44 Pandharipande et al , JAMA 2007 ; 298:2644-53 ) . We undertake sleep study measure circulate inflammatory cytokine modulate sleep patient ALI/ARDS randomize receive two different sedation strategy : central α2 adrenergic sedative-analgesic ( dexmedetomidine ) versus conventional sedation strategy ( midazolam fentanyl ) randomize , double blind , cross-over study . Specific Aim 1 : To assess short-term effect α2 adrenergic agent sleep quality critically ill patient ALI/ARDS . Specific Aim 2 : To assess short-term effect α2 adrenergic agent sleep-modulating inflammatory cytokine critically ill patient ALI/ARDS . Specific aim 3 : To determine effect α2 adrenergic agent in-vitro production sleep-modulating inflammatory cytokine peripheral blood mononuclear cell patient ALI/ARDS . Collectively , study identify whether sleep disruption patient minimize . In long-term , program research identify sedation practice least associated adverse short- long-term consequence critical illness , thereby ultimately help improve quality life patient survive critical illness</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Age range 1885 ( inclusive ) Potential subject receive mechanical ventilation Potential subject must : 1 . Acute hypoxemia PaO2/FiO2 &lt; 300 mm Hg ( ALI ) OR &lt; 200 mm Hg ( ARDS ) , 2 . Bilateral infiltrates ( include mild infiltrates ) 3 . No clinical evidence leave atrial hypertension , pulmonary artery wedge pressure &lt; 18 mm Hg . Potential subject recruit intubation follow ( systolic BP &gt; 90 mm Hg 2 less continuous infusion pressor ) ventilatory parameter ( require &lt; 60 % fractional inspired O2 concentration [ FiO2 ] PEEP &lt; 8 cm H2O ) . Acute myocardial infarction unstable angina active myocardial ischemia Potential subject consider unstable undergo investigation primary physician . 1 . Symptomatic bradycardia ( ventricular rate &lt; 50 accompanied hypotension [ Systolic blood pressure &lt; 90 mm Hg ] atrioventricular block [ second degree type II great ] ) . 2 . Known inability tolerate betablockers dexmedetomidine . 3 . Systolic blood pressure &lt; 90 mmHg despite continuous infusion 2 vasopressor start study drug infusion . Potential subject comatose suffer severe debilitate neurological disease ( Intracerebral hemorrhage ) . History severe dementia ( derive medical record family source ) . Active seizure Alcohol abuse history Clinical evidence decompensated congestive heart failure ( elevated jugular venous distension , dependent edema ) echocardiographic evidence significant systolic heart failure leave ventricular ejection fraction &lt; 30 % . Renal failure ( renal dialysis ) ; Hepatocellular failure ( ChildPugh class C ) . Metastatic terminal cancer patient donotresuscitate order Pregnancy Potential subject expect extubated within 48 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>critical illness</keyword>
	<keyword>sleep</keyword>
	<keyword>polysomnography</keyword>
	<keyword>inflammatory cytokine</keyword>
	<keyword>dexmedetomidine</keyword>
	<keyword>acute lung injury</keyword>
	<keyword>acute respiratory distress syndrome</keyword>
	<keyword>midazolam</keyword>
	<keyword>fentanyl</keyword>
	<keyword>cytokine</keyword>
</DOC>